TITLE

State of research in the field of the creation of plant vaccines for veterinary use

AUTHOR(S)
Permyakova, N.; Uvarova, E.; Deineko, E.
PUB. DATE
January 2015
SOURCE
Russian Journal of Plant Physiology;Jan2015, Vol. 62 Issue 1, p23
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Transgenic plants as an alternative of costly systems of recombinant immunogenic protein expression are the source for the production of cheap and highly efficient biotherapeuticals of new generation, including plant vaccines. In the present review, possibilities of plant system application for the production of recombinant proteins for veterinary use are considered, the history of the 'edible vaccine' concept is briefly summarized, advantages and disadvantages of various plant systems for the expression of recombinant immunogenic proteins are discussed. The list of recombinant plant vaccines for veterinary use, which are at different stages of clinical trials, is presented.
ACCESSION #
100239513

 

Related Articles

  • Efficient Secretion of Recombinant Proteins from Rice Suspension-Cultured Cells Modulated by the Choice of Signal Peptide. Huang, Li-Fen; Tan, Chia-Chun; Yeh, Ju-Fang; Liu, Hsin-Yi; Liu, Yu-Kuo; Ho, Shin-Lon; Lu, Chung-An // PLoS ONE;10/16/2015, Vol. 10 Issue 10, p1 

    Plant-based expression systems have emerged as a competitive platform in the large-scale production of recombinant proteins. By adding a signal peptide, αAmy3sp, the desired recombinant proteins can be secreted outside transgenic rice cells, making them easy to harvest. In this work, to...

  • The Use of Legume Seed for Expression and Storage of High Value Proteins. MORAVEC, TOMÁŠ; ČEŘOVSKÁ, NOEMI // Czech Journal of Genetics & Plant Breeding;2014, Vol. 50 Issue 2, p69 

    There is an ever growing need for the use of recombinant proteins both in medicine and industry; however their widespread use is limited by the lack of production capacity. Transgenic plants offer the possibility to produce and deliver recombinant proteins on a large scale with low production...

  • Scalable Production of a Multifunctional Protein (TSG-6) That Aggregates with Itself and the CHO Cells That Synthesize It. Kim, Dong-Ki; Choi, Hosoon; Nishida, Hidetaka; Oh, Joo Youn; Gregory, Carl; Lee, Ryang Hwa; Yu, Ji Min; Watanabe, Jun; An, Su Yeon; Bartosh, Thomas J.; Prockop, Darwin J. // PLoS ONE;1/21/2016, Vol. 11 Issue 1, p1 

    TNF-α stimulated gene/protein 6 (TNFAIP6/TSG-6) is a multifunctional protein that has a number of potential therapeutic applications. Experiments and clinical trials with TSG-6, however, have been limited by the technical difficulties of producing the recombinant protein. We prepared stable...

  • Increased yield of heterologous viral glycoprotein in the seeds of homozygous transgenic tobacco plants cultivated underground. Tackaberry, Eilleen S.; Prior, Fiona; Bell, Margaret; Tocchi, Monika; Porter, Suzanne; Mehnic, Jelica; Ganz, Peter R.; Sardana, Ravinder; Altosaar, Illimar; Dudani, Anil // Genome;Jun2003, Vol. 46 Issue 3, p521 

    The use of transgenic plants in the production of recombinant proteins for human therapy, including subunit vaccines, is being investigated to evaluate the efficacy and safety of these emerging biopharmaceutical products. We have previously shown that synthesis of recombinant glycoprotein B (gB)...

  • Production of recombinant proteins in plant root exudates. Borisjuk, Nikolai V.; Borisjuk, Ludmyla G.; Logendra, Sithes; Petersen, Frank; Gleba, Yuri; Raskin, Ilya // Nature Biotechnology;May99, Vol. 17 Issue 5, p466 

    The large-scale production of recombinant proteins in plants is limited by relatively low yields and difficulties in extraction and purification. These problems were addressed by engineering tobacco plants to continuously secrete recombinant proteins from their roots into a simple hydroponic...

  • Molecular farming of recombinant antibodies in plants. Schillberg, S.; Fischer, R.; Emans, N. // Cellular & Molecular Life Sciences;Mar2003, Vol. 60 Issue 3, p433 

    : Antibodies represent a large proportion of therapeutic drugs currently in development. In most cases, they are produced in mammalian cell lines or transgenic animals because these have been shown to fold and assemble the proteins correctly and generate authentic glycosylation patterns....

  • Plastoglobules: a new address for targeting recombinant proteins in the chloroplast. Vidi, Pierre-Alexandre; Kessler, Felix; Brehelin, Claire // BMC Biotechnology;2007, Vol. 7, p4 

    Background: The potential of transgenic plants for cost-effective production of pharmaceutical molecules is now becoming apparent. Plants have the advantage over established fermentation systems (bacterial, yeast or animal cell cultures) to circumvent the risk of pathogen contamination, to be...

  • Rebuttal to Peel et al. Re: 'The imperative to develop a human vaccine for the Hendra virus in Australia'. Zahoor, Bilal // Infection Ecology & Epidemiology;2016, Vol. 6, p1 

    A response from the author of the article ‘The imperative to develop a human vaccine for the Hendra virus in Australia' in the 2016 issue is presented which suggests the need for development of the Hendra human vaccine to complement the risk management strategies.

  • VACCINE REPORT.  // BioPharm International;Apr2007, Vol. 20 Issue 4, p16 

    The article reports on the announcement on the clinical trial data from GlaxoSmithKline in London, England. The clinical trials show that the flu vaccine formulated by the company's proprietary adjuvant system works against the H5N1 or the avian influenza. It is hoped that the vaccine help the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics